| Document |
Document Title |
|
WO/2024/100452A2 |
The disclosure relates to a compound represented by Formula 1, or a pharmaceutically acceptable salt thereof, as a stimulator of interferon genes (STING) agonist, pharmaceutical compositions comprising the same, and related methods of an...
|
|
WO/2024/099242A1 |
Provided are a deuterated aminopyridine derivative as represented by formula I, an optical isomer or mixture thereof, a polymorph thereof, a salt thereof, or a hydrate or solvate thereof; further provided is a pharmaceutical composition ...
|
|
WO/2024/099438A1 |
Disclosed in the present invention are compounds as SUMO activating enzyme inhibitors. Particularly, the present invention relates to compounds as represented by general formula (1) and general formula (2) and preparation methods therefo...
|
|
WO/2024/100548A1 |
The present invention relates to the medical use of a compound in the treatment of tumor metastases.
|
|
WO/2024/098193A1 |
Provided is a use of mitochondrial fusion protein 2 (MFN2), an MFN2 variant capable of interacting with SERCA2, or an MFN2 expression promoter in maintaining and/or promoting tumor killing and/or viability of a CD8 T cell. Also provided ...
|
|
WO/2024/099517A1 |
The invention relates to salts of 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. A compound of general formula (IA) or (IB) is provided, where A represents -C=C- and n is 0 or 1; R1 is selected from among the group consisting of...
|
|
WO/2024/076499A3 |
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the s...
|
|
WO/2024/101406A1 |
The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) or liver cancer, the agent containing a material for inhibiting the expression or f...
|
|
WO/2024/099434A1 |
The present disclosure relates to a cucurbituril compound and the medical use thereof. Specifically, the present disclosure relates to a compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a preparation method t...
|
|
WO/2024/076725A3 |
Disclosed are self-regulated chimeric antigen receptors and methods of making the same. Also, disclosed herein are methods of treating a cancer through the administration of NK cells and/or NK T cells comprising said chimeric antigen rec...
|
|
WO/2024/099225A1 |
Disclosed are a class of ULK inhibitors. Specifically, the present invention relates to a compound as represented by general formula (1) and a preparation method therefor, and the use of the compound of general formula (1) and an isomer,...
|
|
WO/2024/099245A1 |
An RGD dimer compound, and a preparation method therefor and a use thereof, relating to the field of nuclear medicine and molecular imaging. The structure of the RGD dimer compound is represented by formula (I) or formula (I-1). Provided...
|
|
WO/2024/099387A1 |
Provided is use of a ligand-medicament conjugate in the treatment of cancer, further, use of a ligand-medicament conjugate in the preparation of a medicament for treating platinum-resistant advanced epithelial ovarian cancer, primary per...
|
|
WO/2024/076967A9 |
The present invention provides compositions and methods for reducing the level and/or activity of a TET protein, for treating or preventing a disease and disorder associated with an increased level and/or activity of a TET protein, for r...
|
|
WO/2024/103042A1 |
The present disclosure is related to improved compositions and methods related to viral immunotherapy treatments for cancer. Specifically, provided herein are therapeutic rAAV vectors, particles, and compositions thereof related to treat...
|
|
WO/2024/099363A1 |
Disclosed are a pharmaceutical composition of a receptor-interacting protein 2 (RIP2) inhibitor in combination with an immune checkpoint inhibitor and use thereof. The present invention provides a pharmaceutical composition comprising an...
|
|
WO/2024/099386A1 |
The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutically acceptable salt the...
|
|
WO/2024/102649A1 |
The present disclosure provides, among other things, methods for treating cancer comprising administering an effective dose of Azenosertib to subjects selected to have a Cyclin E1 status above a predetermined threshold.
|
|
WO/2024/099250A1 |
A myricetin nanomaterial preparation, a preparation method therefor, and a use thereof. The nano-preparation is prepared from a myricetin-Sm III-CuII solution and a polyethylene glycol aqueous solution. The myricetin nanomaterial prepara...
|
|
WO/2024/101859A1 |
The present invention relates to a sustained-release injectable preparation comprising dexamethasone acetate and a preparation method therefor.
|
|
WO/2024/099251A1 |
An imaging agent containing a myricetin nanomaterial, a preparation method therefor, and a use thereof. The imaging agent is prepared from the following components: radionuclides and a myricetin-SmIII-CuII nano-preparation. The radiolabe...
|
|
WO/2024/081729A3 |
Provided herein are antigen-binding protein constructs (ABPCs), antibodies, and antibody drug conjugates (ADCs) that bind LRRC15, and uses of the same.
|
|
WO/2024/100294A1 |
The present invention relates to chimeric antigen receptors (CARs) that target Cadherin-17 (CDH17) and cells comprising said CARs. Methods and uses involving the CARs of the invention are also provided.
|
|
WO/2024/099229A1 |
The present invention relates to a 2-aminopyrimidine compound as represented by general formula (I) and a pharmaceutically acceptable salt, solvate, or prodrug thereof, preparation methods therefor, and a pharmaceutical composition conta...
|
|
WO/2024/098692A1 |
A Wee1 protein kinase degrading agent and a use thereof. Specifically, the compound represented by formula I or a pharmaceutically acceptable salt thereof, and a use thereof in the treatment of proliferative diseases. W-L-D (I).
|
|
WO/2024/102542A1 |
Disclosed herein are compositions comprising siRNAs capable of downregulating SET and MYND (Myeloid-Nervy-DEAF1) domain-containing protein 2 (SMYD2) gene expression or a variant thereof. Also disclosed herein are methods of using SMYD2 i...
|
|
WO/2024/102943A1 |
Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/040220A3 |
Therapeutics which target CD83 show great promise in the treatment and prevention of cancer and immunological disorders. The disclosure provides a fusion protein comprising a CD83 binding domain comprising the amino acid sequences of SEQ...
|
|
WO/2024/101915A1 |
The present invention relates to a peptide nucleic acid complex having enhanced stability and improved inhibitory effects on a target gene, wherein the terminals of a bioactive peptide nucleic acid and a carrier peptide nucleic acid are ...
|
|
WO/2024/102645A1 |
Provided herein, in certain aspects, are methods of treating a prostate cancer in a subject, comprising administering a bispecific anti-CTLA4 x anti-PD1 antibody (e.g., XmAb®20717) in combination with at least one additional agent (e.g....
|
|
WO/2024/101935A1 |
The present invention relates to an amphiphilic conjugate comprising a self-assemblyable peptide and use thereof. A conjugate according to one aspect and a pharmaceutical composition comprising same can be useful in the prevention or tre...
|
|
WO/2024/100200A1 |
The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to L1-CAM (CD171), to a polynucleotide encoding at least one variable heavy chain sequence and/or at least one variable light cha...
|
|
WO/2024/101993A1 |
The invention relates to a targeting system for cancer comprising a cancer treatment moiety, such as radioisotope, with improved therapeutic effect, the use thereof as a medicament, such as for cancers, to a dosage comprising the targeti...
|
|
WO/2024/100046A1 |
The present invention relates to polyplexes comprising linear conjugates of LPEI and PEG. The LPEI and PEG fragments of the linear conjugates are preferably linked by a [3+2] cycloaddition between an azide and an alkene or an alkyne to p...
|
|
WO/2024/102621A1 |
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
|
|
WO/2024/099526A1 |
Disclosed are new compounds comprising two antigen binding sites and a tetramerization site, where the antigen binding sites are selected among natural binding sites. The new compounds have improved manufacturability, stability and solub...
|
|
WO/2024/102791A1 |
Disclosed are compounds of Formula (I): Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein ty...
|
|
WO/2024/099519A1 |
The invention relates to 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. According to the invention, the derivatives comprise a compound of the general formula (I), wherein A represents -C=C- or -C=C-C=C-; R1 is selected from the...
|
|
WO/2024/099339A1 |
Provided is a traditional Chinese medicine composition for treating breast cancer with accompanying psychosomatic symptoms such as anxiety, depression, insomnia and the like. Raw materials of the composition are dried rehmannia root, rad...
|
|
WO/2024/099411A1 |
Provided are a crystal form of a free base of compound I, a salt of compound I and a crystal form of the salt of compound (I). The crystal form and the salt form have excellent effects in terms of physical stability, chemical stability, ...
|
|
WO/2024/099416A1 |
The present invention relates to a fused tricyclic PARP1 inhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to a compound capable of inhibiting poly ADP-ribose polymerase activity, a...
|
|
WO/2024/099241A1 |
The present invention relates to a deuterated pyrimidine derivative represented by formula I or a pharmaceutically acceptable salt, an isomer, a metabolite, a prodrug, a solvate, or a hydrate thereof. The present invention further relate...
|
|
WO/2024/044636A3 |
Compositions, methods, and kits are provided for treating infections and cancer with metallic nanoclusters. In particular, metallic nanoclusters having a size of less than 10 nm that are conjugated to adenosine triphosphate (ATP) or an a...
|
|
WO/2024/102794A1 |
Disclosed are compounds of Formula (I): pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosp...
|
|
WO/2024/099898A1 |
The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...
|
|
WO/2024/102764A1 |
The disclosure relates to methods of treating cancer in a subject administering nucleic acid molecules comprising a nucleic acid sequence encoding a plurality of neoantigens. Vaccines, compositions comprising coding regions encoding neoa...
|
|
WO/2023/034793A9 |
Disclosed herein is the effect that IL-33 has on the tumor microenvironment. In one aspect, disclosed herein are methods for treating a cancer, inhibiting TH2 pro-tumorigenic cytokines in the TME, inhibiting secretion of IL-33 in the TME...
|
|
WO/2024/099398A1 |
Disclosed in the present invention are a class of sulfonamide compounds containing an ortho-fused heterocycle and the use thereof, and specifically disclosed is a compound of formula (II), a stereoisomer or a pharmaceutically acceptable ...
|
|
WO/2024/099487A1 |
The invention relates to oligosaccharides composed of alternating glucose and N- acetylglucosamine units with a double bond in position 4 of the terminal non-reducing saccharide (glucose) and with the primary hydroxyl group in position 1...
|
|
WO/2024/098148A1 |
There is described herein modified T cells engineered to have decreased IRF2 expression and method of making and using the same for cancer therapy.
|
